Hyperhomocystinemia and the Prevalence of Symptomatic Atherosclerotic Vascular Disease in Taiwanese Chronic Hemodialysis Patients: A Retrospective Study

References

• Chauveau P., Chadefaux B., Coude M., Aupettt J., Hannedouche T., Kamoun P., Jungers P. Hyperhomocystinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int. 1993; 41(suppl)S72–S77
   Google Scholar
• Arnadottir M., Brattstrom L., Simonsen O., Thysell H., Hultbero B., Andersson A., Nilsson-Ehle P. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin. Nephrol. 1993; 40: 236–240
   Google Scholar
• Bachmann J., Tepel M., Raidt H., Riezler R., Graefe U., Langer K., Zidek W. Hyperhomocystinemia and the risk for vascular disease in hemodialysis patients. J. Am. Soc. Nephrol. 1995; 6: 121–125
   Google Scholar
• Bostom A.G., Shemin D., Lapane K.L., Miller J.W., Sutherland P., Nadeau M., Seyoum E., Hartman W., Prior R., Wilson P.W.F., Selhub J. Hyperhomocystinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93–103
   Google Scholar
• Robinson K., Gupta A., Dennis V.W., Arheart K., Chaudhary D., Green R., Vigo P., Mayer E.L., Selhub J., Kutner M., Jacobsen D.W. Hyperhomocystinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743–2748
   Google Scholar
• Bostom A.G., Lathrop L. Hyperhomocystinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997; 52: 10–20
   Google Scholar
• Moustapha A., Naso A., Nahlawi M., Gupta A., Arheart K.L., Jacobsen D.W., Robinson K., Dennis V.W. Prospective study of hyperhomocystinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138–141
   Google Scholar
• Manns B.J., Burgess E.D., BSc-Hyndman M.E., Parsons H.G., Schaefer J.P., Scott-Douglas N.W. Hyperhomocystinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am. J. Kid. Dis. 1999; 34: 669–677
   Google Scholar
• Manns B.J., Burgress E.D., Parsons H.G., Schaefer J.P., Hyndman M.E., Scott-Douglas N.W. Hyperhomocystinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int. 1999; 55: 315–320
   Google Scholar
• Moustapha A., Gupta A., Robinson K., Arheart K., Jacobsen D.W., Schreiber M.J., Dennis V.W. Prevalence and determinants of hyperhomocystinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999; 55: 1470–1475
   Google Scholar
• Bostom A.G., Shemin D., Verhoef P., Nadeau M.R., Jacques P.F., Selhub J., Dworkin L., Rosenberg I.H. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: a prospective study. American Heart Association, Inc. 1997; 69: 2554–2558
   Google Scholar
• Bostom A., Brosnan J.T., Hall B., Nadeau M.R., Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116: 59–62
   Google Scholar
• Jacob R.A., Wu M.M., Henning S.M., Swendseid M.E. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J. Nutr. 1994; 124: 1072–1080
   Google Scholar
• Ubbink J.B., Hayward V.W.J., van der Merwe A., Beeker P.J. Vitamin B12, vitamin B6, and folate nutritional status in men with hyperhomocystinemia. Am. J. Clin. Nutr. 1993; 57: 47–53
   Google Scholar
• Tremblay R., Bonnardeaux A., Gradah D., Busque L., Lebrun M., Ouimet D., Leblanc M. Hyperhomocystinemia in hemodialysis patients: effect of 12-month supplementation with hydrosoluble vitamins. Kidney Int. 2000; 58: 851–858
   Google Scholar
• Hultberg B., Andersson A., Sterner G. Plasma homocysteine in renal failure. Clin. Nephrol. 1993; 41: 230–234
   Google Scholar
• Bostom A., Lathrop L. Hyperhomocystinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997; 52: 10–20
   Google Scholar
• Green D., Stone N.J., Krumlovsky F.A. Putative atherogenic factors in patients with chronic renal failure. Prog. Cardiovasc. Dis. 1983; 26: 133–140
   Google Scholar
• Tamura T., Bergman S.M., Morgan S.L., Homocysteine B. vitamins, and vascular-access thrombosis in patients treated with hemodialysis. Am. J. Kid. Dis. 1998; 32: 475–481
   Google Scholar
• Manns B., Hyndman E., Burgess E., Parsons H., Schaefer J., Snyder F., Scott-Douglas N. Oral vitamin B12 and high-dose folic acid in hemodialysis patients with hyper-homocyst (e) inemia. Kidney Int. 2001; 59: 1103–1109
   Google Scholar
• Lasseur C., Parrot F., Delmas Y., Level C., Ged C., Redonnet-Vernhet I., Montaudon D., Combe C., Chauveau P. Impact of high-flux/high-efficiency dialysis on folate and homocysteine metabolism. Journal of Nephrology 2001; 14: 32–35
   Google Scholar
• Chandna S.M., Tattersall J.E., Nevett G., Tew C.J., O'sullivan J., Greenwood R.N., Farrington K. Low serum vitamin B12 levels in chronic high-flux hemodialysis patients. Nephron 1997; 75: 259–263
   Google Scholar